Rafal Al-Saigh

Rafal Al-Saigh

Auto-generated profile, based on publicly available information

Rafal Al-Saigh

Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HAHussam Al-Humadi
Hussam Al-Humadi
RARafal J. Al-Saigh
Rafal J. Al-Saigh
AAAhmed W. Al-Humadi
Ahmed W. Al-Humadi
Tuberculosis (TB) is a highly contagious disease that still poses a threat to human health. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse ways in order to survive in a variety of host lesions and to subsequently evade immune surveillance; as a result, fighting TB and its associated multidrug resistance has been an ongoing challenge. The aim of this review article is to summarize the historical sequence of drug development and use in the fight against TB, with a particular emphasis on the decades between World War II and the dawn of the twenty first century (2000).

1 January 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
RARafal Al-Saigh
Rafal Al-Saigh
AVAristea Velegraki
Aristea Velegraki
TWThomas J. Walsh
Thomas J. Walsh
EREmmanuel Roilides
Emmanuel Roilides
LZLoukia Zerva
Loukia Zerva
In conventional ΜΙC tests, fungi are exposed to constant drug concentrations, whereas in vivo, fungi are exposed to changing drug concentrations. Therefore, we developed a new in vitro pharmacokinetic/pharmacodynamic model where human plasma pharmacokinetics of standard doses of 1 mg/kg amphotericin B, 4 mg/kg voriconazole, and 1 mg/kg caspofungin were simulated and their pharmacodynamic characteristics were determined against three clinical isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus terreus with identical MICs (1 mg/liter for amphotericin B, 0.5 mg/liter for voriconazole) and minimum effective concentrations (0.5 mg/liter for caspofungin). This new model consists of an internal compartment (a 10-ml dialysis tube made out of a semipermeable cellulose membrane allowing the free diffusion of antifungals but not galactomannan) inoculated with Aspergillus conidia and placed inside an external compartment (a 700-ml glass beaker) whose content is diluted after the addition of antifungal drugs by a peristaltic pump at the same rate as the clearance of the antifungal drugs in human plasma. Fungal growth was assessed by galactomannan production. Despite demonstrating the same MICs, amphotericin B completely inhibited (100%) A. fumigatus but not A. flavus and A. terreus, whose growth was delayed for 7.53 and 22.8 h, respectively. Voriconazole partially inhibited A. fumigatus (49.5%) and Α. flavus (27.9%) but not Α. terreus; it delayed their growth by 3.99 h (A. fumigatus) and 5.37 h (Α. terreus). Caspofungin did not alter galactomannan production in all of the species but A. terreus. The new model simulated human pharmacokinetics of antifungal drugs and revealed important pharmacodynamic differences in their activity.

1 April 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AEAntigoni Elefanti
Antigoni Elefanti
JMJohan W. Mouton
Johan W. Mouton
KKKaterina Krompa
Katerina Krompa
RARafal Al-Saigh
Rafal Al-Saigh
PVPaul Verweij
Paul Verweij
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
Given the high protein binding rates of antifungal drugs and the effect of serum proteins on Aspergillus growth, we investigated the in vitro pharmacodynamics of amphotericin B, voriconazole, and three echinocandins in the presence of human serum, assessing both inhibitory and fungicidal effects. In vitro inhibitory (IC) and fungicidal (FC) concentrations against 5 isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus terreus were determined with a CLSI M38-A2-based microdilution method using the XTT methodology after 48 h of incubation at 35°C with a medium supplemented with 50% human serum. In the presence of serum, the IC and FC of amphotericin B and the IC of echinocandins were increased (1.21- to 13.44-fold), whereas voriconazole IC and FC were decreased (0.22- to 0.90-fold). The amphotericin B and voriconazole FC/IC ratios did not change significantly (0.59- to 2.33-fold) in the presence of serum, indicating that the FC increase was due to the IC increase. At echinocandin concentrations above the minimum effective concentration (MEC), fungal growth was reduced by 10 to 50% in the presence of human serum, resulting in complete inhibition of growth for some isolates. Thus, the in vitro activities of amphotericin B and echinocandins were reduced, whereas that of voriconazole was enhanced, in the presence of serum. These changes could not be predicted by the percentage of protein binding, indicating that other factors and/or secondary mechanisms may account for the observed in vitro activities of antifungal drugs against Aspergillus species in the presence of serum.

1 October 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RAR. Al-Saigh
R. Al-Saigh
AEA. Elefanti
A. Elefanti
AVA. Velegraki
A. Velegraki
LZL. Zerva
L. Zerva
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
The pharmacodynamics (PD) of voriconazole activity against Aspergillus spp. were studied using a new in vitro dynamic model simulating voriconazole human pharmacokinetics (PK), and the PK-PD data were bridged with human drug exposure to assess the percent target (near-maximum activity) attainment of different voriconazole dosages. Three Aspergillus clinical isolates (1 A. fumigatus, 1 A. flavus, and 1 A. terreus isolate) with CLSI MICs of 0.5 mg/liter were tested in an in vitro model simulating voriconazole PK in human plasma with Cmax values of 7, 3.5, and 1.75 mg/liter and a t1/2 of 6 h. The area under the galactomannan index-time curve (AUCGI) was used as the PD parameter. In vitro PK-PD data were bridged with population human PK of voriconazole exposure, and the percent target attainment was calculated. The in vitro PK-PD relationship of fAUC0-24-AUCGI followed a sigmoid pattern (global R2 = 0.97), with near-maximum activities (10% fungal growth) observed at an fAUC0-24 (95% confidence interval [CI]) of 18.9 (14.4 to 23.1) mg · h/liter against A. fumigatus, 26.6 (21.1 to 32.9) mg · h/liter against A. flavus, and 36.2 (27.8 to 45.7) mg · h/liter against A. terreus (F test; P < 0.0001). Target attainment for 3, 4, and 5 mg/kg-of-body-weight voriconazole dosages was 24% (11 to 45%), 80% (32 to 97%), and 93% (86 to 97%) for A. fumigatus, 12% (5 to 26%), 63% (17 to 93%), and 86% (73 to 94%) for A. flavus, and 4% (2 to 11%), 36% (6 to 83%), and 68% (47 to 83%) for A. terreus. Based on the in vitro exposure-effect relationships, a standard dosage of voriconazole may be adequate for most patients with A. fumigatus but not A. flavus and A. terreus infections, for which a higher drug exposure may be required. This could be achieved using a higher voriconazole dosage, thus highlighting the usefulness of therapeutic drug monitoring in patients receiving a standard dosage.

1 August 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
RARafal Al-Saigh
Rafal Al-Saigh
MSMaria Siopi
Maria Siopi
NSNikolaos Siafakas
Nikolaos Siafakas
AVAristea Velegraki
Aristea Velegraki
LZLoukia Zerva
Loukia Zerva
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
Conventional MIC testing of amphotericin B results in narrow MIC ranges challenging the detection of resistant strains. In order to discern amphotericin B pharmacodynamics, the in vitro activity of amphotericin B was studied against Aspergillus isolates with the same MICs by using a new in vitro pharmacokinetic/pharmacodynamic (PK/PD) model that simulates amphotericin B human plasma levels. Clinical isolates of Aspergillus fumigatus , A. terreus , and A. flavus with the same Clinical and Laboratory Standards Institute modal MICs of 1 mg/liter were exposed to amphotericin B concentrations following the plasma concentration-time profile after single-bolus administration with C max values of 0.6, 1.2, 2.4, and 4.8 mg/liter. Fungal growth was monitored for up to 72 h based on galactomannan production. Complete growth inhibition was observed only against A. fumigatus with amphotericin B with a C max of ≥2.4 mg/liter. At the lower C max values 0.6 and 1.2 mg/liter, significant growth delays of 34 and 52 h were observed, respectively ( P < 0.001). For A. flavus , there was no complete inhibition but a progressive growth delay of 1 to 50 h at an amphotericin B C max of 0.6 to 4.8 mg/liter ( P < 0.001). For A. terreus , the growth delay was modest (up to 8 h) at all C max s ( P < 0.05). The C max (95% confidence interval) associated with 50% activity for A. fumigatus was 0.60 (0.49 to 0.72) mg/liter, which was significantly lower than for A. flavus 3.06 (2.46 to 3.80) mg/liter and for A. terreus 7.90 (5.20 to 12.29) mg/liter ( P < 0.001). A differential in vitro activity of amphotericin B was found among Aspergillus species despite the same MIC in the order A. fumigatus > A. flavus > A. terreus in the in vitro PK/PD model, possibly reflecting the different concentration- and time-dependent inhibitory/killing activities amphotericin B exerted against these species.

5 May 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Verified
Journal Article
Closed access
FAFarah W. Al-Humadi
Farah W. Al-Humadi
HQHiba Waleed Qassim
Hiba Waleed Qassim
AHAli Majeed Hameed
Ali Majeed Hameed
AAAli Jihad Hamid Al-Athari
Ali Jihad Hamid Al-Athari
BUBushra Jaber Umran
Bushra Jaber Umran
RARafal J. Al-Saigh
Rafal J. Al-Saigh
An intrauterine system (IUS) is a type of contraception tool that is used in order to control fertility and prevent concep¬tion in women for a long period. The aim of this study was to assess the influence of copper- versus levonorgestrel-releasing IUSs on women’s health. This is a descriptive cross-sectional study of 75 women that were randomly se¬lected (50 women that used a copper-releasing IUS and the remaining 25 that used a levonorgestrel-releasing IUS) amongst those attending out patient’s clinics at Hillah, Iraq, from March to July 2016. All women were between 18 to 46 years of age, and have had an IUS for at least three months. The measurement of serum ceruloplasmin (SCerP), haemoglobin, vitamin D (VD), interleukin-6 (IL-6), and interferon-gamma (IFN-γ) levels was undertaken. Our results revealed that the copper-releasing IUS group has low haemoglobin and VD levels, along with high levels of SCerP and proinflammatory cytokines. One the other hand, the levonorgestrel-releasing IUS group displayed no significant changes on the above markers. We can conclude that the levonorgestrel-releasing IUS is free of any adverse effect when compared to a copper-releasing IUS, at least with regard to the parameters examined by our study.